Altria Group (MO), a Dividend King with 56 consecutive years of dividend growth, offers a 6.3% forward dividend yield and has delivered 18% annualized returns over five years, outperforming the S&P 500. However, the company lags in smoke-free product innovation compared to competitor Philip Morris International, with 88% of revenue still from smokeable products. Despite past failures in smoke-free ventures, modest success in future smokeless products could significantly boost valuations, making it an attractive buy-and-hold opportunity for dividend investors.

Philip Morris International's plans to expand its IQOS heated tobacco device in India have been blocked as the country maintains its e-cigarette ban despite years of lobbying efforts. Despite India being the world's seventh-largest cigarette market and a significant revenue contributor for PM, the ban remains in place. The setback comes as PM's smoke-free products have been driving growth globally, with IQOS reaching over 35 million users worldwide.

Consumer staples stocks are significantly outperforming the broader market amid recent volatility in tech and crypto sectors. The Consumer Staples Select Sector SPDR Fund (XLP) surged nearly 6% last week and is up 11.89% year-to-date, driven by the sector's defensive nature and steady demand for essential goods. The sector recently broke out of a multi-year consolidation, with strong technical momentum and institutional support suggesting further upside potential.

The article compares two consumer staples ETFs: XLP offers pure-play exposure to consumer defensive stocks with a low 0.08% expense ratio and 36 holdings anchored by Walmart and Costco, while IYK provides broader diversification with 54 holdings including healthcare and basic materials at a higher 0.38% fee. XLP delivered stronger 5-year returns ($1,302 vs $1,222 on $1,000 invested) despite similar dividend yields, making it the more cost-efficient choice for defensive investors seeking pure sector exposure.

Investors are rotating from technology stocks into consumer staples in early 2026 due to concerns over high tech valuations, AI momentum sustainability, and broader economic uncertainties including a weakening jobs market. The Consumer Staples ETF (XLP) has risen 13% year-to-date, significantly outperforming the technology sector's 3% decline. Leading staples companies like Philip Morris and Coca-Cola are benefiting from their defensive characteristics, offering stable earnings, consistent dividends, and lower volatility.

Philip Morris International significantly exceeded earnings expectations with EPS of $7.54 vs. $1.70 expected and revenue of $10.4B vs. $10.39B expected, driven by strong growth in smoke-free products. Biogen also beat estimates with EPS of $1.99 vs. $1.61 expected, boosted by strong sales of LEQEMBI and SKYCLARYS. Centene reported mixed results but beat both EPS and revenue expectations. All three companies provided positive 2026 guidance.

IYK (iShares US Consumer Staples ETF) outperforms PBJ (Invesco Food & Beverage ETF) with lower fees (0.38% vs 0.61%), higher dividend yield (2.6% vs 1.8%), and stronger 1-year returns (7.7% vs 0.7%). IYK offers broader diversification across consumer staples and healthcare, while PBJ's concentrated food and beverage focus exposed it to sector headwinds like rising ingredient costs and private-label competition.

Geoffrey Seiler recommends five stocks across different investment styles: Amazon and Chewy as attractively valued e-commerce operators with strong growth; Philip Morris International as a defensive growth stock benefiting from smoke-free products; Dutch Bros as a pure growth play expanding rapidly; and JAKKS Pacific as a cheap turnaround play with upcoming blockbuster movie catalysts.

Philip Morris International presented scientific evidence to the FDA's Tobacco Products Scientific Advisory Committee seeking a modified-risk tobacco product (MRTP) label for its ZYN nicotine pouches. The company aims to communicate to adult smokers that switching completely to ZYN reduces risks of six smoking-linked diseases including lung cancer, heart disease, and stroke. The FDA's materials indicated the proposed claim is scientifically accurate, and PM shares rose 1.09% following the announcement.

The article recommends Amazon and Philip Morris International as attractive buys. Amazon benefits from strong e-commerce operating leverage driven by robotics and AI investments, accelerating AWS cloud revenue growth, and attractive valuation compared to peers. Philip Morris International is gaining momentum with its smoke-free portfolio, particularly its Zyn nicotine pouches and Iqos heated tobacco products, which offer higher unit economics than traditional cigarettes.

The global consumer healthcare market is experiencing a structural shift where regulatory compliance and FDA approval have become critical competitive advantages. Major companies including Philip Morris, Celsius Holdings, USANA Health Sciences, and Medifast are advancing strategic initiatives focused on regulatory readiness, product integration, and market expansion. Doseology Sciences has partnered with McKinney Regulatory Science Advisors to strengthen its FDA pathway for oral pouch products.

The article recommends adding to positions in Amazon and Philip Morris International. Amazon is benefiting from strong operating leverage in e-commerce, growth in AWS cloud services, and leadership in AI and digital advertising. Philip Morris International is positioned as a growth stock in a defensive industry, with strong momentum in its smokeless products like Zyn and Iqos. Both stocks are considered attractively valued for 2026.